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Abstract
We investigated the efficacy of pharmacotherapy and psychotherapy for depression by searching for RCT’s. Studies were
classified according to chronicity and severity and a meta-analysis was applied. Ten studies were included. Remission did not
differ between psychotherapy (38%) and pharmacotherapy (35%). No differences were found in chronic, or in non-chronic
depression, and in mild or in moderate depression. Both treatments performed better in mild than in moderate depression.
Dropout was larger in pharmacotherapy (28%) than in psychotherapy (24%). At follow-up relapse in pharmacotherapy
(57%) was higher than in psychotherapy (27%). Psychotherapy and pharmacotherapy appear equally efficacious in
depression. Both treatments have larger effects in mild than in moderate depression, but similar effects in chronic and non-
chronic depression and at follow-up psychotherapy outperforms pharmacotherapy.
In the past 25 years, a number of reviews and meta-
analyses comparing the efficacy of psychotherapy
and pharmacotherapy in depression have been
conducted (e.g., Casacalenda, Perry, & Looper,
2002; DeRubeis, Gelfand, Tang, & Simons, 1999;
Dobson, 1989; Gloaguen, Cottraux, Cucherat, &
Blackburn, 1998; Hollon, Jarrett, et al., 2005;
Hollon, Shelton, & Loosen, 1991; Hollon, Thase,
& Markowitz, 2002; Jarrett, 1995; Robinson,
Berman, & Neimeyer, 1990; Royal Australian and
New Zealand College of Psychiatrists, 1983;
Steinbrueck, Maxwell, & Howard, 1983; Weissman,
Jarrett, & Rush, 1987; Wexler & Cicchetti, 1992). It
has been argued that many of these reviews and
meta-analyses present methodological limitations.
They often do not provide intention-to-treat (ITT)
analyses, present effect sizes from which obviously
no remission rates can be deduced, include flawed
studies (e.g., studies that did not use standardized
diagnostic criteria), and present response rates
instead of remission rates (Casacalenda et al.,
2002). An even more important limitation may be
the striking methodological and clinical heterogene-
ity of the studies included in most reviews and meta-
analyses. Clinical heterogeneity refers to differences
in patient samples, treatment protocols, and treat-
ment settings across studies. We mention three
examples. In Casacalenda et al.’s meta-analysis
(2002), three trials regard primary care patients,
whereas the other three trials consider psychiatric
outpatients. Treatment duration varies from 10 to 34
weeks. Psychotherapy conditions include cognitive
therapy and interpersonal psychotherapy as well as
problem-solving therapy and social work counseling.
In the meta-analysis of Gloaguen et al. (1998),
settings vary even more, including hospital patients,
outpatients, volunteers, students, adolescents, and
geriatric patients. Treatment duration varies from 4
to 79 weeks. Not surprisingly, the authors frequently
report that the hypothesis of intertrial homogeneity
was rejected. The review of Hollon, Jarrett, et al.
(2005) considers primary care, geriatric and adult
in- and outpatients suffering from dysthymia or
major depressive disorder (MDD). Although some
of the reviewers (e.g., Gloaguen et al., 1998) do
address the issue of heterogeneity, most of the
reviews and meta-analyses mentioned previously do
not include statistical analyses assessing the influ-
ence of the clinical heterogeneity on the review
outcome. Clinical heterogeneity among studies in-
cluded in reviews or meta-analyses makes data
pooling hazardous (see Cochrane Reviewers’ Hand-
book 4.2.2; Cochrane Collaboration, 2004). It cer-
tainly does not allow specific conclusions regarding
particular patients groups or settings. Heterogeneity
may provide a partial explanation for the rather
inconsistent conclusions reached by different re-
views. Many of them conclude that psychotherapy
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and pharmacotherapy are equally efficacious, but
some deduce that psychotherapy outperforms phar-
macotherapy (Dobson, 1989; Gloaguen et al., 1998;
Royal Australian and New Zealand College of
Psychiatrists, 1983; Steinbrueck et al., 1983;
Weissman et al., 1987). In this article, we present
the results of a meta-analysis based on randomized
controlled trials (RCTs) published between 1980
and 2005, comparing psychotherapy with pharma-
cotherapy in adult psychiatric outpatients with non-
psychotic unipolar depression.
We increased clinical homogeneity among studies
by applying rather strict inclusion criteria regarding
patient samples, diagnoses, and treatment settings
(see Appendix). Subsequently, we statistically tested
the heterogeneity among the included studies to
assess the extent to which we had achieved clinical
homogeneity. Thus, studies were selected on the
basis of clinical criteria only. Statistical heterogeneity
analysis was not used as a selection criterion but as a
test run afterward. The primary research question
regards the relative efficacy of pharmacotherapy and
psychotherapy in the acute treatment of depression
assessed at treatment termination and at follow-up.
The secondary question regards possible differences
in dropout rates during treatment. We took into
consideration two variables known to influence
treatment prognosis: chronicity and severity. To
that end, we differentiated among mild, moderate,
and severe depression and between chronic and
nonchronic depression.
Method
Search Strategy
A systematic search for RCTs was performed in
MEDLINE, EMBASE, Cochrane Controlled Trials
Register, Cochrane Database of Reviews and Proto-
cols, and PsychInfo. Search headings were DE-
PRESSION, MAJOR DEPRESSIVE DISORDER,
PSYCHOTHERAPY, PHARMACOTHERAPY,
ANTIDEPRESSANTS. Limits were (randomised
controlled trial[Publication Type] OR controlled
clinical trial[Publication Type] OR randomised con-
trolled trials OR random allocation OR double-blind
method OR single-blind method OR clinical
trial[Publication Type] OR clinical trials OR (clinical
AND trial*) OR ((singl* OR doubl* OR trebl* OR
tripl*) AND (blind* OR mask*)) OR placebos
OR placebo* OR random* OR research design OR
comparative study OR evaluation studies OR follow
up studies OR prospective studies OR control OR
controlled OR prospective* OR volunteer*) NOT
(Animal[MESH] NOT (Human[MESH] AND
Animal[MESH])) and a time limit of 1980 (the
year that Diagnostic and Statistical Manual of Mental
Disorders (3rd ed. [DSMIII] was published) until
2005. Titles and abstracts were screened. References
of the retrieved articles were searched. Book chap-
ters on treatment of depression were retrieved. No
special efforts were made to discover unpublished
data. Figure A1 is a quorum flow diagram of the
process and results of literature search.
To obtain a clinically rather homogeneous sample,
several selection criteria were applied. To be in-
cluded, the study should compare psychotherapy
with pharmacotherapy and focus on efficacy of acute
treatment (no maintenance treatment or sequential
treatment). The study sample should consist of
psychiatric outpatients (no primary care patients or
inpatients), aged between 19 and 65 years (no
geriatric patients or children), diagnosed with uni-
polar major depression according to DSMIIIR
(American Psychiatric Association, 1980), DSM
IVR (American Psychiatric Association, 1994),
or research diagnostic criteria (Spitzer et al.,
1978). Treatment protocols in the studies should
apply a formal (according to behavioral, cognitive,
psychodynamic, or client-centered theories and
techniques), time-limited (maximum 6 months)
individual psychotherapy and an adequate treatment
with regular antidepressants (i.e., an adequate dose
[different per antidepressant] administered during
an adequate time period [at least 4 weeks] by a
registered clinician). A regular antidepressant is
approved as such by national authorities. Method
sections were checked for the specifics of the
treatment regimen, but no efforts were made to
obtain additional information. The study should
report remission rates and dropout rates. Methodo-
logical quality was judged according to four criteria
of Cochrane Collaboration:
1. The study should have a randomized design to
minimize selection bias.
2. Apart from the treatments, the two study
groups must have been treated equally to
minimize performance bias.
3. The study should report on selective dropout in
the treatment conditions (e.g., have ITT ana-
lyses or specify differences in dropout).
4. Detection bias should be minimized by blind
assessment of outcomes.
Two reviewers, who needed to agree on all criteria in
order to include a study, judged all selection criteria
independently. No studies were excluded because of
reviewer disagreement.
The main outcome of the meta-analysis was
efficacy at treatment termination, expressed in
remission rates, and at follow-up, expressed in
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relapse rates. Remission rates were pooled calculat-
ing the relative risk (RR) and the odds ratio (OR).
The relative risk is the ratio between the risks of an
event (e.g., remission) in group A and in group B.
The odds ratio is the ratio between two odds: the
odds on an event in group A and the odds on the
same event in group B. Both an odds ratio and a
relative risk amounting to 1 signify that there is no
difference between the two treatments. Numbers
needed to treat (NNT) were calculated, indicating
the number of patients who would need to be treated
with treatment A to produce one recovery from
depression, which would not have occurred had they
been given treatment B. The dropout rates and
relapse rates were pooled calculating the relative risk.
Remission rates at treatment termination were
pooled in an ITT sample (i.e., a sample consisting
of all randomized patients). Relapse rates at follow-
up were pooled against all patients remitted at
treatment termination.
All data were analyzed using the Review Manager
4.2 software of the Cochrane Collaboration. Dichot-
omous data (relative risk and odds ratio) were
analyzed using the Mantel-Haenszel fixed-effects
model with 95% confidence intervals. Our analyses
included a formal test of statistical heterogeneity.
Statistical heterogeneity is the variability in the
treatment effects in the different studies. It is a
consequence of clinical or methodological diversity
among these studies. Statistical heterogeneity occurs
when the observed treatment effects are more
different from each other than one would expect
based on random chance alone. Significant hetero-
geneity suggests that the studies are not estimating
the same quantity. The heterogeneity test we used
was the natural approximate chi-square test; non-
significant results (using p/.10 as a limit) indicate a
lack of evidence for heterogeneity in the results. The
test also describes the percentage of the variability in
effect estimates (I2) resulting from heterogeneity
rather than to sampling error. An I2 of more than
50% indicates notable heterogeneity (Cochrane Re-
viewers’ Handbook 8.7.2; Cochrane Collaboration,
2004).
All analyses were also performed in subsamples
regarding chronicity and severity of the depression.
First, studies regarding chronic depression (the
majority of patients were diagnosed as presenting
with depression lasting at least 2 years) were
differentiated from studies regarding nonchronic
depression. Second, using the mean baseline scores
on the 17-item Hamilton Depression Rating Scale
(HDRS; Hamilton, 1967), studies regarding mild
(1219 points), moderate (2024 points), and
severe (25 points or more) depression were differ-
entiated.
Outcome of the Literature Search
The quorum flow diagram in the Appendix shows
the process and results of the literature search.
Table I lists the studies considered suitable for our
review. As can be seen in Table I, our meta-analysis
is based on 10 studies that, taken together, include
1,233 patients (640 treated with pharmacotherapy
and 593 treated with psychotherapy). In Elkin et al.
(1989), there were two psychotherapy conditions
(cognitivebehavioral therapy [CBT] and interper-
sonal therapy [IPT]). In Blackburn and Moore
(1997), there were two antidepressants groups. We
decided to combine the similar treatment groups in
these two studies. Entering two comparisons for
each study in the meta-analysis would violate the
assumption that all comparisons in a meta-analysis
should be independent (Cooper & Hedges, 1994).
Chronic Versus Nonchronic Depression. We found
eight studies of nonchronic depression (Blackburn &
Bishop, 1981; Blackburn, Bishop, Glen, Whalley, &
Christie, 1981; Blackburn & Moore, 1997; Elkin
et al., 1989; Hautzinger, de Jong-Meyer, Treiber,
Rudolf, & Thien, 1996; Hollon et al., 1992;
Murphy, Carney, Knesevich, Wetzel, & Withworth,
1995; Murphy, Simons, Wetzel, & Lustman, 1984)
and three of chronic depression (DeRubeis et al.,
2005; Jarrett et al., 1999; Keller et al., 2000). In the
Keller study, 35% of the patients suffered from
chronic major depression, 42% from MDD plus
dysthymia, and 23% from recurrent depression
without complete remission between episodes,
which in our opinion signifies that all patients
suffered from chronic depression. In the DeRubeis
study, 90% of the patients had chronic or recurrent
depression. Mean duration of the last episode was
7.5 years in the Keller study, 46 months in the
DeRubeis study, and 73 months (in the psychother-
apy group) and 50 months (in the pharmacotherapy
group) in the Jarrett study.
Mild Versus Moderate Depression. Eight studies
provided 17-item HDRS mean baseline scores.
The Jarrett et al. study, however, used the 21-item
version and the Keller study the 24-item version. We
used the O’Sullivan, Fava, Agustin, Baer, and
Rosenbaum (1997) report to translate the 21- and
24-item scores into 17-item scores. The authors
found a ratio of 1.098 between the 21-item and 17-
item HDRS and a ratio of 1.25 between the 24-item
and 17-item HDRS. We calculated that the mean
baseline scores in the Jarrett et al. study, 21.1 points
(psychotherapy) and 20.3 points (pharmacother-
apy), correspond to 19 (21.1/1.098) and 18
(20.3/1.098) 17-item HDRS points, respectively.
568 S. De Maat et al.
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Table I. Studies Included in the Meta-Analysis
Study Treatment Duration/sessions
Pre-Tx HDRSa
 post-Tx
Remission
(n /N ) (%)
Dropout
(n /N ) (%) Comment
Blackburn et al. (1981) Cognitive therapy (n/17) 20 weeks/23 18.96.8 8/17 (47) 3/17 (18) Combined therapy not included.
Outpatients only. Remission definition: HDRS5/
9, BDI5/8. Relapse: At 24 months relapse is
defined by physicians indicating symptoms that
need treatment (Blackburn et al., 1986).
Pharmacotherapy (amitriptyline
or clomipramine) (n/16)
20 weeks 17.48.3 10/16 (63) 3/16 (19)
Murphy et al. (1984) Cognitive therapy (n/24) 12 weeks/20 18.87.7 12/24 (50) 5/24 (21) Combined therapy and cognitive therapy/
placebo conditions not included. Remission
definition: HDRS5/7. Relapse: BDI score/15
(Simons et al., 1986).
Pharmacotherapy (nortriptyline)
(n/24)
12 weeks 20.910.9 8/24 (33) 8/24 (33)
Elkin et al. (1989) IP psychotherapy (n/63) 16 weeks/1620 19.69.8 26/63 (41) 16/63 (25) Placebo Tx condition not included. Remission
definition: HDRS5/6. Relapse: 2 weeks
symptoms meeting RDC for MDD (Shea et al.,
1992).
Cognitive therapy (n/62) 16 weeks/1620 19.610.7 21/62 (34) 25/62 (40)
Pharmacotherapy (imipramine)
(n/57)
16 weeks 19.59.8 24/63 (38) 26/63 (41)
Hollon et al. (1992) Cognitive therapy (n/25) 12 weeks/20 24.113.3 8/25 (32) 9/25 (36) Combined therapy not included. Remission
definition: HDRS5/6. Relapse: 2 DBI scores/15
separated by 1 week (Evans et al., 1992).
Pharmacotherapy (imipramine)
(n/ 57)
12 weeks 23.814.2 19/57 (33) 25/57 (44)
Murphy et al. (1995) Cognitive therapy (n/11) 16 weeks/20 15.72.27 11/11 (100) 0/11 (0) Relaxation therapy condition not included.
Remission definition: HDRS5/7.Pharmacotherapy (desipramine)
(n/12)
16 weeks 16.49.70 4/12 (33) 5/12 (42)
Hautzinger et al. (1996) CBT (n/40) 8 weeks/24 22.98.5 (c) 14/40 (35) 10/40 (25) Combination therapy not included. Outpatients
only. Remission definition: BDI & HDRS5/9.
Relapse: IDS score/29.
Pharmacotherapy (amitriptyline)
(n/38)
8 weeks 25.18.8 (c) 9/38 (24) 18/38 (47)
Blackburn & Moore (1997) Cognitive therapy (n/27) 16 weeks/16 19.910.7 8/27 (30) 3/27 (11) Only acute treatment phase included. Two
pharmacotherapy groups are pooled. Remission
definition: HDRS5/6.
Pharmacotherapy (physician
choice) (n/48)
16 weeks 20.211.4 9/48 (19) 10/48 (21)
20.813.3
Jarrett et al. (1999) Cognitive therapy (n/ 36) 10 weeks/20 21.110.2a 21/36 (58) 5/36 (14) Placebo condition not included. Study considered
atypical depression. Remission definition:
HDRS5/9.
Pharmacotherapy (phenelzine)
(n/ 36)
10 weeks 20.38.6a 21/36 (58) 9/36 (25)
Keller et al. (2000) Cognitivebehavioral analysis
system (n/228)
12 weeks/1620 26.415.1b 72/228 (32) 55/228 (24) Combined therapy not included. Study
considered chronic depression. Remission
definition: HDRS5/8.Pharmacotherapy (nefazodone)
(n/226)
12 weeks 26.814.7b 64/226 (28) 59/226 (26)
Hollon, DeRubeis et al.
(2005)
Cognitive therapy (n/60)
Pharmacotherapy (paroxetine)
(n/120)
16 weeks/2024
16 weeks
M baseline
whole
sample: 23.4
24/60 (40)
55/120 (46)
9/60 (15)
19/120 (16)
Placebo condition not included. 90% of patients
have chronic or recurrent depression. Remission
definition: HDRS5/7. Relapse: 2 weeks meeting
criteria MDD or HDRS/13 (Hollon et al.,
2005).
Note. HDRS/Hamilton Depression Rating Scale; BDI/Beck Depression Inventory; IP/interpersonal; Tx/treatment; RDC/research diagnostic criteria; MDD/major depressive disorder;
CBT/cognitivebehavioral therapy; IDS/Inventory of Depressive Symptomatology.
a21-item HDRS. b24-item HDRS; modified intention to treat.
E
ffica
cy
of
p
sy
ch
oth
era
p
y
a
n
d
p
h
a
rm
a
coth
era
p
y
for
d
ep
ression
5
6
9
D
o
w
n
l
o
a
d
e
d
 
B
y
:
 
[
V
r
i
j
e
 
U
n
i
v
e
r
s
i
t
e
i
t
,
 
L
i
b
r
a
r
y
]
 
A
t
:
 
0
9
:
2
4
 
2
5
 
N
o
v
e
m
b
e
r
 
2
0
1
0
The mean baseline score of 27 points in the Keller
study corresponds to 22 (27/1.25) 17-item HDRS
points.
In all, we found five studies of (on average) mild
depression (Blackburn et al., 1981; Elkin et al.,
1989; Jarrett et al., 1999; Murphy et al., 1984, 1995)
and five of (on average) moderate depression
(Blackburn & Moore, 1997; DeRubeis et al., 2005;
Hautzinger et al., 1996; Hollon et al., 1992; Keller
et al., 2000). We did not find suitable studies
regarding severe depression.
Follow-Up Studies. Six publications reported fol-
low-up data. Hollon, DeRubeis, et al. (2005) add
follow-up data to DeRubeis et al. (2005); Evans
et al. (1992) to Hollon et al. (1992); Shea et al.
(1992) to Elkin et al. (1989); Simons, Murphy,
Levine, and Wetzel (1986) to Murphy et al. (1984);
and Blackburn, Eunson, and Bishop (1986) to
Blackburn et al. (1981). Hautzinger et al. (1996)
report follow-up data in their own publication.
Patients did not relapse if they (a) were remitted
after acute treatment and (b) did not meet criteria
for depression at follow-up. There were differences
across studies in the definition of relapse (see Table I
for the definitions of remission and relapse per
study). In most studies, follow-up was naturalistic
(i.e., there was no control for receiving treatment
during follow-up). In three studies (Evans et al.,
1992; Shea et al., 1992; Simons et al., 1986), the
authors provided data on reentering treatment dur-
ing follow-up. However, we based our analyses on
the relapse data defined by cutoff scores or depres-
sion criteria and not on definitions that included
‘‘reentering treatment.’’ There were considerable
differences between follow-up phases across studies.
Follow-up durations varied from 1 year (Hautzinger
et al., 1996; Hollon et al., 1992; Simons et al.,
1986) to 1.5 year (Shea et al., 1992) and 2 years
(Blackburn et al., 1986; Evans et al., 1992). In the
Blackburn et al. study, treatment was continued for
6 months in the so-called follow-up period (anti-
depressants at a normal regimen, psychotherapy at a
6-weekly booster session regimen). In the Shea et al.
study, both pharmacotherapy and psychotherapy
were gradually reduced in 4 to 6 weeks after
termination. Furthermore, in this study, we com-
bined the results of both psychotherapy conditions
because entering two comparisons for each study in
the meta-analysis would violate the assumption that
all comparisons in a meta-analysis should be inde-
pendent (Cooper & Hedges, 1994). In the follow-up
data of Hautzinger et al., no differentiation was
made between inpatients and outpatients. In Simons
et al., medication was tapered before being discon-
tinued at treatment termination. In Hollon et al.,
one medication group received a placebo after
treatment termination, whereas the other group
continued medication. We included only the first
group in our analysis. Patients who had been treated
with psychotherapy in the Hollon et al. study
received three booster sessions. The Evans et al.
study had a medication continuation group and a
noncontinuation group. We included only the latter
in our meta-analysis.
Results
Dropout Rates
The dropout rates are shown in Figure 1. As can be
seen, the pooled dropout rate in pharmacotherapy
(28.43%) is larger than that in psychotherapy
(23.6%). The difference (4.83%) is statistically
significant (RR/1.29, p/.009). The chi-square
test of heterogeneity indicates a lack of evidence for
heterogeneity (p/0.73 and I2/0%).
Study  Pharmacotherapy  Psychotherapy RR (fixed)  Weight RR (fixed) 
n/N n/N 95% CI % 95% CI 
Blackburn,1981        3/16               3/17  2.17     1.06 [0.25, 4.52]
Murphy, 1984        8/24               5/24
  3.74     1.60 [0.61, 4.19]
Elkin,1989       26/63              41/125   20.54  1.26 [0.85, 1.85]   
Hollon,1992       25/57               9/25  9.35     1.22 [0.67, 2.22]
Murphy, 1995        5/12               0/11  0.39    10.15 [0.63, 164.77]
 Hautzinger, 1996       18/38              10/40  7.28     1.89 [1.01, 3.57]
Blackburn,1997       10/48               3/27  2.87     1.88 [0.56, 6.23]
Jarrett, 1999        9/36               5/36  3.74     1.80 [0.67, 4.85]
Keller, 2000       59/226             55/228 40.94     1.08 [0.79, 1.49]
DeRubeis, 2005       19/120              9/60    8.97     1.06 [0.51, 2.19]   
Total (95% CI) 640                593 100.00     1.29 [1.07, 1.57]
Total events: 182 (Pharmacotherapy), 140 (Psychotherapy)
Test for heterogeneity: Chi² = 6.11, df = 9 (P = 0.73), I² = 0%
Test for overall effect: Z = 2.61 (P = 0.009)
0.1 0.2 0.5 1 2 5 10
Favous pharmacotherapyr Favous psychotherapyr
Figure 1. Relative risk of dropout in psychotherapy versus pharmacotherapy.
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Efficacy at Treatment Termination
Relative Risk of Remission. Figure 2 shows the
remission rates and relative risk for remission. As can
be seen, the pooled remission rate for psychotherapy
(37.94%) is somewhat larger than for pharmacother-
apy (34.84%), but the difference (3.1%) is not
statistically significant (pooled RR/0.91, p/.24).
The chi-square test of heterogeneity indicates a lack
of evidence for heterogeneity (p/.23 and I2/
23.7%).
Chronicity. Table II separately shows the relative
risk for remission in the three studies of chronic
depression and the eight studies of nonchronic
depression. As can be seen, the pooled remission
rates of psychotherapy and pharmacotherapy do not
differ significantly in chronic depression (36.11%
and 36.64%, respectively, p/.83) and in nonchronic
depression (41.14% and 32.17%, respectively,
p/.12). In both analyses, the chi-square test of
heterogeneity indicates that there is no evidence
for heterogeneity (nonchronic: p/0.14/I2/38%;
chronic: p/ .58/I2/0%). It also appears that the
pooled remission rates of chronic and nonchronic
depression do not differ significantly for psychother-
apy (36.11% and 41.14%, respectively, p/.31) and
pharmacotherapy (36.64% and 32.17%, respec-
tively, p/.25). In the last two analyses, heterogene-
ity was not an issue because we made only one
comparison between two groups of studies.
Severity. Table III separately shows the relative
risk for remission in the five studies of mild depres-
sion and the five studies of moderate depression.
The pooled remission rates of psychotherapy and
pharmacotherapy do not differ significantly in mild
depression (46.47% and 44.37%, respectively, p/
.34) and moderate depression (33.15% and 31.90%,
respectively, p/.44). In the analysis of moderate
depression, no evidence for heterogeneity was found
(p/.55/I2/0%), but in the analysis of mild depres-
sion the chi-square test of heterogeneity indicated
moderate heterogeneity (p/.07/I2/54.3%). This is
possibly due to the outlying results of Murphy et al.
(1984), which, compared with the other studies,
show a larger difference in remission between
psychotherapy (100%) versus pharmacotherapy
(33%). The pooled remission rates of mild and
moderate depression do differ significantly both for
psychotherapy (46.47% and 33.15%, respectively,
p/.001) and pharmacotherapy (44.37% and
31.90%, respectively, p/ .003). In the last two
analyses, heterogeneity was not an issue because
we made only one comparison between two groups
of studies.
Odds Ratio of Remission. Figure 3 shows the odds
ratios for remission. The pooled OR is 0.87, and the
difference between pharmacotherapy and psy-
chotherapy is not statistically significant (p/.24).
The chi-square test of heterogeneity indicates no
evidence for heterogeneity (p/.30 and I2/16%).
The odds ratios in subanalyses regarding chroni-
city and severity of depression do not indicate any
statistically significant differences between the two
treatments in chronic (p/.82) and nonchronic (p/
.12) depression or in mild (p/.35) and moderate
(p/.44) depression. All chi-square tests indicate a
lack of evidence for heterogeneity (ps/.58, .17, .10,
and .58, respectively).
Numbers Needed to Treat
Pooled data show that 32 patients would need to be
treated with psychotherapy to produce one recovery
from depression, which would not have occurred
had they been given antidepressants (NNT/32;
1/0.031).
Study Pharmacotherapy Psychotherapy  RR (fixed)  Weight RR (fixed) 
n/N n/N 95%CI % 95%CI
Blackburn,1981       10/16               8/17  3.49     1.33 [0.71, 2.50]
Murphy, 1984        8/24              12/24  5.40     0.67 [0.33, 1.33]
Elkin,1989       24/63              47/125 14.16     1.01 [0.69, 1.49]
Hollon,1992       19/57               8/25  5.00     1.04 [0.53, 2.05]
Murphy, 1995        4/12              11/11  5.16     0.33 [0.15, 0.74]
Hautzinger, 1996        9/38              14/40  6.13     0.68 [0.33, 1.38]
Blackburn,1997        9/48               8/27  4.60     0.63 [0.28, 1.45]
 Jarrett, 1999       21/36            21/36        9.44     1.00 [0.68, 1.48]
Keller, 2000       64/226             72/228 32.23     0.90 [0.68, 1.19]
DeRubeis, 2005       55/120             24/60 14.39     1.15 [0.79, 1.65]
Total (95%CI) 640                593 100.00     0.91 [0.79, 1.06]
Total events: 223 (Pharmacotherapy), 225 (Psychotherapy)
Test for heterogeneity:Chi² = 11.80,df= 9 (P= 0.23), I² = 23.7%
Test for overall effect: Z = 1.18 (P= 0.24)
0.2 0.5 1 2 5
Favours psychothotherapy Favours pharmacotherapy
Figure 2. Relative risk of remission in psychotherapy versus pharmacotherapy.
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Efficacy at Follow-Up
Figure 4 shows the relative risk of relapse during
follow-up. There is a statistically significant differ-
ence (RR/0.46, pB/.0001) between the pooled
relapse rate of pharmacotherapy (56.56%) and that
of psychotherapy (26.51%). The chi-square test of
heterogeneity indicates that the results lack evidence
of heterogeneity (p/.68, I2/0%). Because there
was considerable clinical heterogeneity in the follow-
up phases across studies, we performed various
analyses on subgroups of studies. First, we excluded
the study of Hollon, Jarrett, et al. (2005). We
consider it an outlier because the patients treated
with medication received placebos throughout the
follow-up period. Second, we discriminated between
follow-up durations (combining the studies with
1-year follow-up and combining studies with 1.5-
to 2-year follow-ups). All subanalyses showed results
similar to those of the overall analysis (i.e., a
significant difference in favor of psychotherapy).
The homogeneity hypothesis was not rejected in
any of these analyses.
Discussion
We performed a meta-analysis comparing psy-
chotherapy and pharmacotherapy in the treatment
of adult psychiatric outpatients suffering from mild
to moderate major depression. In contrast to existing
reviews, our meta-analysis furthered homogeneity of
the included studies by applying strict clinical
inclusion and exclusion criteria. We performed
statistical tests a posteriori supporting our argument
that the included studies were indeed sufficiently
homogeneous. In addition, we took into account two
potential determinants of treatment prognosis by
performing subanalyses on chronicity and severity of
depression.
Psychotherapy and pharmacotherapy appeared
equally effective at treatment termination. This
means that in the long-standing controversy regard-
ing the relative effectiveness of both treatment
modalities, our results support the ‘‘no difference’’
point of view.
According to clinical lore, chronicity and severity
influence the relative effectiveness of the two ther-
apeutic modalities. However, we found no differ-
ences in efficacy between both treatments in chronic
and nonchronic depression and in mild and moder-
ate depression. Understandably, but unfortunately,
we found no data regarding severe depression.
Our results show that severity, in contrast to
chronicity, affects the efficacy of both treatments.
They have superior results in mild depression
compared with moderate depression. This may
indicate that monotherapies are not the first choice
in moderate depression (HDRS/20). This hypoth-
esis is supported by the findings of Thase et al.
(1997), who report a statistically significant and
clinically relevant difference in favor of combined
therapy over psychotherapy in more severe
(HDRS/19), but not less severe (HDRSB/20),
depression. Several reviews and meta-analyses
(Friedman et al., 2004; Hegerl, Plattner, & Mo¨ller,
2004; Hollon, Jarrett, et al., 2005; Pampallona,
Bollini, Tibaldi, Kupelnick, & Munizza, 2004)
report superior results of combined treatment com-
pared with medication alone, especially for more
severe depressed patients.
The parity in efficacy found at treatment termina-
tion does not seem to last beyond actual treatment.
Table II. ITT Remission Rates in Studies of Chronica and Nonchronicb Depression
Variable Psychotherapy Pharmacotherapy Significance
Studies of chronic depression 36.11% 36.64% RR/0.98, p/.83
Studies of nonchronic depression 41.14% 32.17% RR/0.83, p/.12
Significance RR/0.90, p/.31 RR/1.14, p/.25
Note. ITT/intention to treat; RR/relative risk.
aJarrett et al., 1999; Keller et al., 2000; DeRubeis et al., 2005. bBlackburn et al., 1981; Murphy et al., 1984; Elkin et al., 1989; Hollon et al.,
1992; Murphy et al., 1995; Hautzinger et al., 1996; Blackburn & Moore, 1997.
Table III. ITT Remission Rates in Studies of Milda and Moderateb Depression
Variable Psychotherapy Pharmacotherapy Significance
Studies of mild depression 46.47% 44.37% RR/0.90, p/.34
Studies of moderate depression 33.15% 31.90% RR/0.92, p/.44
Significance RR/1.40, p/.001 RR/1.39, p/.003
Note. ITT/intention to treat; RR/relative risk.
aBlackburn et al., 1981; Murphy et al., 1984, 1995; Elkin et al., 1989; Jarrett et al., 1999. bHollon et al., 1992; Hautzinger et al., 1996;
Blackburn & Moore, 1997; Keller et al., 2000; DeRubeis et al., 2005.
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Our follow-up data show that twice as many patients
relapse after pharmacotherapy termination than
after psychotherapy termination. According to our
results, the idea that short-term therapies yield
short-lived effects applies more to pharmacotherapy
than to psychotherapy. The difference might even be
larger than presented here, because in two of the six
follow-up studies we included (Blackburn et al.,
1986; Hollon et al., 1992) the study design seems to
favor pharmacotherapy above psychotherapy. In the
Blackburn et al. study, pharmacotherapy was con-
tinued for 6 months, whereas psychotherapy was
provided only at a 6-weekly booster session regimen.
In the Hollon et al. study, medication was substi-
tuted by placebo during the follow-up period,
whereas patients treated with psychotherapy re-
ceived only three booster sessions. Furthermore, in
the Evans et al. and Simons et al. studies, more
pharmacotherapy patients than psychotherapy pa-
tients sought treatment during follow-up, possibly
indicating a relapse that was not accounted for in our
relapse data. Our findings regarding relapse are
comparable to those reported in the reviews of
Hollon, Jarrett, et al. (2005) and Gloaguen et al.
(1998). In addition, the follow-up studies of Hollon,
DeRubeis, et al. (2005) and Evans et al. (1992) show
that psychotherapy patients are no more likely to
relapse than pharmacotherapy patients who keep
taking medication. In our opinion, our relapse data,
apart from obvious clinical implications, are highly
relevant for establishing costbenefit ratios, a topic
that is not addressed in this review nor in the
included RCTs.
We found that dropout rates in pharmacotherapy
are significantly higher than in psychotherapy,
although the difference (5%) is not impressive. As
researchers and clinicians alike know, medication
nonadherence is a major problem in pharmacother-
apy. Still, psychotherapy too is beset with the
problem of noncompliance, because 20% to 25%
of patients drop out.
Our review has several limitations. First, conclu-
sions based only on the results of RCTs have well-
known limitations. An obvious one is selection bias.
RCTs leave patients with serious comorbidity, such
as drug dependence, suicide intentions, or severe
personality disorders, out of scope. In fact, the
majority of suitable patients do not end up in
RCTs as a result of all inclusion and exclusion
criteria that have to be met. Keitner, Posternak, and
Study  Pharmacotherapy  Psychotherapy  OR (fixed)  Weight  OR (fixed)
 n/N  n/N  95% CI  %  95% CI
 Blackburn, 1981       10/16               8/17          2.05      1.88 [0.47, 7.53]        
 Murphy, 1984                   8/24              12/24          5.64      0.50 [0.16, 1.61]        
 Elkin, 1989                     24/63              47/125        13.75      1.02 [0.55, 1.91]        
 Hollon, 1992             
      19/57               8/25          5.23      1.06 [0.39, 2.90]        
 Murphy, 1995              
       4/12              11/11          5.51      0.02 [0.00, 0.49]        
 Hautzinger, 1996          9/38              14/40          7.34      0.58 [0.21, 1.55]        
 Blackburn, 1997                 9/48               8/27          5.87      0.55 [0.18, 1.64]        
 Jarrett, 1999                  21/36              21/36          6.17      1.00 [0.39, 2.55]        
 Keller, 2000                   64/226             72/228        36.23      0.86 [0.57, 1.28]        
 DeRubeis, 2005            
      55/120             24/60         12.22      1.27 [0.68, 2.38]        
Total (95% CI) 640                593 100.00      0.87 [0.68, 1.10]
Total events: 223 (Pharmacotherapy), 225 (Psychotherapy)
Test for heterogeneity: Chi² = 10.72, df = 9 (P = 0.30), I² = 16.0%
Test for overall effect: Z = 1.18 (P = 0.24)
 0.2  0.5  1  2  5
 Favours psychotherapy  Favours pharmacotherapy
Figure 3. Odds ratio of remission rates of psychotherapy versus pharmacotherapy.
Study Psychotherapy Pharmacotherapy RR (fixed)  Weight RR (fixed) 
n/N n/N 95%CI % 95%CI
Shea,1992       16/44               9/18       20.98     0.73 [0.40, 1.33]       
Evans, 1992        2/10               5/10        8.21     0.40 [0.10, 1.60]       
Simons, 1986        0/10               1/9         2.58     0.30 [0.01, 6.62]     
Hautzinger, 1996        5/27               8/19       15.43     0.44 [0.17, 1.14]       
Blackburn,1986        1/6                6/8         8.45     0.22 [0.04, 1.39]       
Hollon,2005       11/35             27/35       44.35     0.41 [0.24, 0.69]       
Total (95%CI) 132                99 100.00     0.46 [0.33, 0.65]
Total events: 35 (Psychotherapy), 56 (Pharmacotherapy)
Test for heterogeneity:Chi² = 3.13,df= 5 (P= 0.68), I² = 0%
Test for overall effect: Z = 4.38 (P< 0.0001)
0.1 0.2 0.5 1 2 5 10
Favours psychotherapy Favours pharmacotherapy
Figure 4. Relative risk of relapse rates.
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Ryan (2003), for example, mention that only 14.5%
of eligible depressed patients eventually took part in
an RCT. Second, our meta-analysis only compares
psychotherapy with pharmacotherapy, leaving com-
parisons with combined therapy out of scope. Third,
efficacy was measured with the HDRS only. Most of
the studies we found did not assess social function-
ing or quality of life, which are the ultimate goals of
therapy. Some studies measured depression with
other scales, such as the Beck Depression Inventory
(BDI; Beck, Ward, Mendelson, Mock, & Erbaugh,
1961). Because it was not our aim to compare scales,
and we used the HDRS as inclusion criterion, we did
not perform a meta-analysis on the BDI. However, it
certainly would be interesting to perform meta-
analyses based on both scales. Fourth, the metho-
dological quality of the included studies varied.
Some studies of actual treatment (Blackburn et al.,
1981; Murphy et al., 1995) and all follow-up studies
were characterized by small sample sizes, lacking
statistical power to detect differences. Although
some studies (e.g., the Keller study) controlled for
medication compliance, most did not. In short, only
the two more recent studies (Hegerl et al., 2004;
Sackett, 1998) correspond well to actual research
criteria. Fifth, allegiance effects (Gaffan, Tsaousis, &
Kemp-Wheeler, 1995) cannot be excluded.
Perhaps more important than these limitations is
that we based our conclusions concerning severity of
depression on mean baseline scores of the studies,
not on individual patient data. We are aware that this
is a rather rough division of a spectrum. Never-
theless, our results do not seem to diverge from
findings based on individual patients. Blackburn and
Moore (1997), Hollon et al. (1992), Hautzinger
et al. (1996), and Elkin et al. (1989) performed
subanalyses on severity. They too did not find
significant differences between psychotherapy and
pharmacotherapy in less severe (HDRSB/20) and
more severe (HDRS/19) depressed patients. Our
HDRS cutoff scores for the distinction among mild,
moderate, and severe depression are in accordance
with what is mostly found in literature. Unfortu-
nately, Hamilton did not define cutting scores for his
scale. The result is that there are no generally
accepted definitions of mild, moderate, and severe
depression. According to clinical lore, mild depres-
sion and moderate depression range, respectively,
from 1214 to 1820 and from 1820 to 2426
HDRS points (17-tem version).
Finally, although our approach explicitly aimed to
further homogeneity, it cannot be denied that the
included studies still present some heterogeneity.
Psychotherapy includes cognitive therapy and inter-
personal therapy; pharmacotherapy includes tricyc-
lic antidepressants (TCAs) and selective serotonin
reuptake inhibitors (SSRIs). The importance of this
point, however, may be limited because meta-analy-
tic studies found no significant differences between
TCAs and SSRIs (Anderson, 2000) or between
psychodynamic therapy and CBT (Leichsenring,
2001) in the treatment of depressed outpatients.
Only one study in our meta-analysis considered IPT;
the remaining studies applied CBT. Therefore, it
may be argued that our conclusions do not merit
psychotherapy per se but apply mainly to cognitive
therapy. Treatment durations varied, and, although
the differences in psychotherapy sessions across
studies are limited, the efficacy of pharmacotherapy
might be somewhat weighted down by studies with
relatively short treatment periods (e.g., Hautzinger
et al., 1996). The definition of remission differs per
study, with cutoff scores varying from 6 to 9 HDRS
points. This is quite a disparity; according to Jonghe
and Swinkels (2005), most researchers agree that a
difference of 3 points borders on clinical signifi-
cance. The follow-up studies are obviously hetero-
geneous in various clinical aspects, so much so that
we were somewhat surprised to find all the tests in
this area indicating strong homogeneity of the
results. There are no generally accepted definitions
of relapse. Most authors applied more or less strict
HDRS or MDD criteria, but some (e.g., Evans et al.,
1992; Shea et al., 1992; Simons et al., 1986)
included ‘‘reentering treatment’’ in one of their
relapse definitions. It appears that more pharma-
cotherapy patients than psychotherapy patients re-
enter treatment during follow-up. This might have
underestimated the relapse rates for pharmacother-
apy in our study. All in all, pooling these data is
debatable, and interpretation of the relapse rates
should be done cautiously. Our results, however, are
corroborated by the studies of Hollon, Jarrett, et al.
(2005) and Gloaguen et al. (1998), who simply
listed relapse rates of individual trials, not pooling
the data, and came to comparable conclusions.
We conclude that depressed patients profit equally
from psychotherapy and pharmacotherapy after
short-term treatment. Furthermore, it may be con-
cluded that they seem to benefit more from psy-
chotherapy than from pharmacotherapy during the
1- to 2-year follow-up period.
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Appendix
Potentially relevant RCT’s identified in
literature search and screened for retrieval
(n = 1.601)
RCT’s relevant for more detailed evaluation
(n = 75)
RCT’s excluded based on screening of
titles and abstracts (n = 1.526) 
Second screening of publications retrieved
and screened (n = 26)
Publications excluded based on
therapy (n = 6), inpatients (n = 2), double
publication (n = 2), methodological 
(n = 6). Total: 16
RCT’s included in meta-analysis (n = 10) 
Publications excluded based on
primary care (n = 5), age (n = 5), design
(n = 13), therapy (n = 12), inpatients
(n = 6), other (n = 8). Total:49
Figure A1. Quorum flow diagram.
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Zusammenfassung
Die relative Effizienz von Psychotherapie und
Pharmakotherapie bei der Behandlung von
Depressionen: Eine Meta-Analyse
Wir haben die Effektivita¨t von Pharmakotherapie und
Psychotherapie bei Depression mit Hilfe von randomi-
sierten kontrollierten Studien untersucht. Zur Durchfu¨h-
rung einer Meta-Analyse wurden Untersuchungen nach
Chronizita¨t und Schweregrad von Depression klassifiziert.
10 Studien wurden beru¨cksichtigt. Die Remissionen
zeigten keinen Unterschied zwischen Psycho- (35%)
und Pharmakotherapie (38%). Es gab auch keine Un-
terschiede bei chronischen und nichtchronischen
Depressionen und im Vergleich von leichten und mittel-
schweren Depressionen. Beide Behandlungen waren bes-
ser bei leichten als bei mittelschweren Depressionen.
Dropout war gro¨ßer bei Pharmakotherapie (28%) als
bei Psychotherapie (24%). Die Rezidivraten bei der
Katamnese waren ho¨her bei Pharmako- (57%) als bei
Psychotherapie (27%). Psychotherapie und Pharma-
kotherapie erscheinen gleichermaßen effizient bei der
Behandlung von Depressionen, beide Behandlungen zei-
gen gro¨ßere Effekte bei leichter als bei mittelschwerer
Depression und a¨hnliche Effekte bei chronischer und bei
nicht-chronischer Depression. Bei katamnestischen Erhe-
bungen ist die Psychotherapie jedoch der Pharmakother-
apie u¨berlegen.
Re´sume´
L’efficacite´ respective de la psychothe´rapie et de la
pharmacothe´rapie dans le traitement de la
de´pression : une me´ta-analyse
Nous avons investigue´ l’efficacite´ de la pharmacothe´rapie
et de la psychothe´rapie de la de´pression en re´coltant des
RCTs.Les e´tudes e´taient classe´es en fonction de la
chronicite´ et de la se´ve´rite´ pour eˆtre soumises a` une
me´ta-analyse. Dix e´tudes e´taient inclues. La re´mission
e´tait la meˆme entre psychothe´rapie (38%) et pharma-
cothe´rapie (35%). Le facteur chronicite´ comme la distinc-
tion entre de´pression le´ge`re et moyenne n’aboutissaient
pas a` des diffe´rences entre les approches. Les deux
traitements obtenaient de meilleurs re´sultats pour la
de´pression le´ge`re que la de´pression moyenne. L’arreˆt
pre´coce e´tait plus fre´quent dans la pharmacothe´rapie
(28%) que dans la psychothe´rapie (24%). A la catamne`se,
la rechute e´tait plus fre´quente apre`s la pharmacothe´rapie
(57%) qu’apre`s la psychothe´rapie (27%). La psychothe´r-
apie et la pharmacothe´rapie semblent avoir la meˆme
efficacite´ dans le traitement de la de´pression. Les deux
traitements sont plus efficaces dans la de´pression le´ge`re, ne
se distinguent pas pour ce qui concerne les de´pressions
chroniques et non-chroniques, et sur le plan catamnes-
tique, la psychothe´rapie s’ave`re plus puissante que la
pharmacothe´rapie.
Resumen
Eficacia relativa de la psicoterapia y la
farmacoterapia en el tratamiento de la depresio´n.
Un meta-ana´lisis
Hemos investigado la eficacia de la fa´rmacoterapia y la
psicoterapia para la depresio´n por medio de los RCT. Los
estudios se clasificaron de acuerdo con la cronicidad y
severidad de los casos y se les aplico´ metaana´lisis. Se
incluyeron diez estudios. La remisio´n no difirio´ entre
psicoterapia (38%) y fa´rmacoterapia (35%). No se en-
contraron diferencias entre la depresio´n cro´nica y la no
cro´nica ni entre la leve y la moderada. Ambos tratamientos
fueron ma´s efectivos en la depresio´n leve que en la
moderada. El abandono fue mayor en la farmacoterapia
(28%) que en la psicoterapia (24%). En el seguimiento, la
recaı´da fue mayor en fa´rmacoterapia (57%) que en
psicoterapia (27%). La psicoterapia y la fa´rmacoterapia
aparecen como igualmente eficaces en la depresio´n.
Ambos tratamientos tienen mayores efectos en la depre-
sio´n leve que en la moderada pero efectos similares en la
depresio´n cro´nica y no cro´nica y en el seguimiento la
psicoterapia supera a la fa´rmacoterapia.
Resumo
A efica´cia relativa da psicoterapia e da
farmacoterapia no tratamento da depressa˜o: uma
meta-ana´lise
Investiga´mos a efica´cia da farmacoterapia e da psicoterapia
para a depressa˜o procurando ensaios clı´nicos randomiza-
dos (ECR). Os estudos foram classificados de acordo com
a cronicidade e severidade e aplicou-se uma meta-ana´lise.
Foram incluı´dos dez estudos. A taxa de remissa˜o na˜o foi
diferente na psicoterapia (38%) e na farmacoterapia
(35%). Na˜o se encontraram diferenc¸as na depressa˜o
cro´nica ou na˜o cro´nica nem na depressa˜o leve ou
moderada. Ambos os tratamentos obtiveram melhores
resultados com depresso˜es leves do que em moderadas.
Os nı´veis de abandono foram mais elevados na farm-
acoterapia (28%) que na psicoterapia (24%). No segui-
mento (follow-up) ha´ mais recaı´das com a farmacoterapia
(57%) do que com a psicoterapia (27%). A psicoterapia e a
farmacoterapia parecem ser igualmente eficazes na depres-
sa˜o. Ambos os tratamentos possuem maiores efeitos na
depressa˜o leve que na moderada, mas efeitos similares na
depressa˜o cro´nica e na˜o-cro´nica, e no seguimento (follow-
up) a psicoterapia e´ mais eficaz que a farmacoterapia.
Sommario
Rispettiva efficacia della psicoterapia e
farmacoterapia nel trattamento della depressione:
una meta-analisi
Abbiamo studiato l’efficacia della farmacoterapia e della
psicoterapia per la depressione cercando studi di RCT. Gli
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studi erano classificati secondo la cronicita` e la gravita` e
un’meta-analisi.
Erano inclusi dieci studi. La remissione non ha differito
fra la psicoterapia (38%) e la farmacoterapia (35%).
Nessuna differenza e` stata trovata nei cronici, o nella
depressione non cronica, lieve o moderata. Entrambi i
trattamenti hanno prestazioni migliori nella forma lieve
che nella depressione moderata. Il dropout era maggiore
nel trattamento farmacoterapico (28%) che in quello
psicoterapico (24%). Al follow-up la percentuale di
ricaduta in farmacoterapia (57%) era superiore alla
psicoterapia (27%). La psicoterapia e la farmacoterapia
sembrano ugualmente efficaci nella cura della depressione.
Entrambi i trattamenti hanno effetti piu` grandi nella forma
lieve che nella depressione moderata, ma nella depressione
cronica e non cronica, al follow-up, la psicoterapia fornisce
risultati migliori rispetto alla farmacoterapia.
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